shares of Cardiff Oncology Inc (CRDF) on
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.